CTLA4 and cancer: Currently, immune checkpoint inhibitor (ICI) therapy is considered as a solution to treat unresectable cancer and is one of adjuvant therapies after surgery.[33] The current study showed CTLA4, HAVCR2, LAG3, PDCD1, and TIGIT expression were significantly elevated in high-risk group and were positively correlated with risk score.